Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DARA

(DARA) (DARA) Stock Price, News & Analysis

(DARA) logo

About (DARA) Stock (NASDAQ:DARA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.32
$0.33
52-Week Range
N/A
Volume
13,850 shs
Average Volume
118,843 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Receive DARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (DARA) and its competitors with MarketBeat's FREE daily newsletter.

DARA Stock News Headlines

The Dollar Reset Nobody’s Talking About
Could this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard economist who has some radical ideas about the U.S. dollar. Today, he reports directly to the Oval Office and has proposed a potential "Mar-a-Lago Accord," which could send the dollar falling by as much as 40% or more. One analyst who predicted the 2008 crisis says the plan may save the country. But if you're unprepared, it WILL be a national nightmare.
GET READY TO MEET YOUR DIGITAL TWIN
See More Headlines

DARA Stock Analysis - Frequently Asked Questions

(DARA) (NASDAQ:DARA) issued its quarterly earnings results on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.14). The specialty pharmaceutical company earned $1.18 million during the quarter, compared to the consensus estimate of $0.83 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that (DARA) investors own include Castleton Technology (CTP), Richland Resources Ltd (RLD.L) (RLD), Thor Energy (THR), Global Invacom Group (GINV), Legendary Investments (LEG), iPass (IPAS) and Aeterna Zentaris (AEZS).

Company Calendar

Last Earnings
11/02/2015
Today
6/19/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DARA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:DARA) was last updated on 6/20/2025 by MarketBeat.com Staff
From Our Partners